Rezolute, Inc.
RZLT
Positions held
Your positionsRZLT isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $448.79M | Enterprise value | $341.92M | Trailing P/E | — | Forward P/E | -9.90 |
| PEG | — | Price / book | 4.44 | Beta | 0.54 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -59.0% | ROA | -35.3% | Debt / equity | 0.01 |
| Current ratio | 9.68 | Free cash flow | -$36.37M | Analyst recommendation | strong_buy | Mean target | $9.80 |
| 52w high | $11.46 | 52w low | $1.07 |
Quarterly
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — | — |
| Net income | -$16.2M | -$22.8M | -$18.1M | -$24.4M | -$18.9M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$17.4M | -$24.2M | -$19.8M | -$25.9M | -$20.0M |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$74.4M | -$68.5M | -$51.8M | -$41.1M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$79.9M | -$70.4M | -$56.0M | -$41.6M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · Cantor Fitzgerald Upgrades Rezolute to Overweight From Neutral
2026-10-05 · Rezolute Gets FDA Nod For Pre-BLA Meeting Despite Phase 3 Miss — Retail Expects ‘Huge Rerating’
2026-10-05 · Rezolute Says FDA Recommends Pre-BLA Meeting for Congenital Hyperinsulinism Treatment
2026-09-29 · Craig-Hallum Upgrades Rezolute to Buy From Hold, Price Target is $7
2026-09-24 · Rezolute Fiscal Q4 Loss Narrows
2026-09-24 · Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update
2026-09-09 · Sector Update: Healthcare Stocks Softer Late Afternoon
2026-09-09 · Sector Update: Healthcare Stocks Decline in Afternoon Trading
2026-09-09 · Rezolute FDA Review Continues After Phase 3 sunRIZE Study Missed Primary Endpoint
2026-09-09 · Rezolute Says FDA Still Reviewing Ersodetug Data From Phase 3 Congenital Hyperinsulinism Study
2026-09-09 · Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
Price (daily)
Full chart · RSI · MACD · patterns